EZH2-Mediated Epigenetic Suppression of GDF15 Predicts a Poor Prognosis and Regulates Cell Proliferation in Non-Small-Cell Lung Cancer

Xiyi Lu,1,6 Xuezhi He,2,6 Jun Su,3,6 Jing Wang,2,6 Xinyin Liu,1 Kun Xu,1 Wei De,4 Erbao Zhang,5 Renhua Guo,1 and Yuenian Eric Shi1

1Department of Oncology, First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, China; 2Department of Anatomy, Histology and Embryology, The Research Center for Bone and Stem Cells, Nanjing Medical University, Nanjing, Jiangsu 211166, China; 3Department of Oncology, The Affiliated Jiangyin Hospital of Southeast University Medical College, Jiangyin, Jiangsu 214400, China; 4Department of Biochemistry and Molecular Biology, Nanjing Medical University, Nanjing, Jiangsu 211166, China; 5Department of Epidemiology and Biostatistics, Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Personalized Medicine, School of Public Health, Nanjing Medical University, Nanjing, Jiangsu 211166, China

Growth differentiation factor 15 (GDF15), a member of the TGF-β superfamily of cytokines, has been reported to exert very heterogeneous functions in various tumors. However, its expression and roles in mediating non-small-cell lung cancer (NSCLC) progression remain unknown. In this study, we found that GDF15 is downregulated in paired NSCLC tissues and correlated with poor clinical outcomes in NSCLC. A functional experiment demonstrated that overexpression of GDF15 significantly repressed NSCLC proliferation both in vitro and in vivo. Mechanistic studies reveal that inhibition of EZH2 expression prevented its binding to the GDF15 promoter region and reduced the trimethylation modification pattern of H3K27. Together, our data uncover that GDF15 is a direct target of EZH2 and, as a regulator of proliferation, might serve as a candidate prognostic biomarker and target for new therapies in human NSCLC.

INTRODUCTION

Lung cancer is one of the leading causes of cancer-related mortality worldwide. Non-small-cell lung cancer (NSCLC), which is the dominant form of lung cancer, is an early asymptomatic disease that constitutes a major global health problem. Despite the development of progressive therapeutic strategies in lung cancer research, the 5-year survival rate among NSCLC patients remains around 15% of diagnosed cases.1,2 Therefore, a better understanding of the molecular mechanisms underlying NSCLC development and progression is needed to develop more effective therapeutic options.

Growth differentiation factor 15 (GDF15), also known as macrophage inhibitory cytokine-1 (MIC-1), NSAID-activated gene (NAG-1), placental transformation growth factor-β (PTGFβ), and placental bone morphogenetic protein (PLAB), is a secreted protein with homology to members of the transforming growth factor β (TGF-β) superfamily.3 GDF15 is highly expressed in the placenta and adult prostate and at lower levels in fetal brain, liver, kidney, and pancreas.3–5 Previous investigations revealed that GDF15 is an important regulator of intestinal adenoma growth and may act as a tumor suppressor gene.6,7 Additionally, some nonsteroidal anti-inflammatory drugs (NSAIDs) induce apoptosis in colon cancer cells, which is possibly mediated by induction of GDF15.8,9 GDF15 has also been reported to reduce cell adhesion and induce caspase-dependent apoptosis in prostate cancer.10,11 In malignant gliomas, GDF-15 can promote cell proliferation and protects malignant glioma cells from natural killer (NK) and T cell-mediated cytotoxicity.12 Similarly, GDF15 could suppress macrophage surveillance, which is regulated by nuclear factor κB (NF-κB) during early human pancreatic adenocarcinoma development.13 These findings suggest that the tissue-specific GDF15 exerts diverse biological functions in tumors that remain largely obscure. To date, the role and detailed mechanisms of GDF15 in NSCLC tumorigenesis have not been elucidated.

In the present study, we aimed to explore whether GDF15 could be a key tumor suppressor gene which epigenetically repression mediated by EZH2 in NSCLC, and our findings provide new insights into the mechanisms of NSCLC tumorigenesis and support the potential of GDF15 as a therapeutic target in NSCLC treatment.
RESULTS
GDF15 Expression Was Downregulated in NSCLC Tissues and Associated with a Poor Prognosis

To initiate our investigation of GDF15, we first determined the GDF15 expression levels in 66 paired NSCLC samples and normal lung tissues by qRT-PCR, normalizing to GAPDH expression. The \( \Delta Ct \) value was determined by subtracting the GAPDH Ct value from the GDF15 Ct value. Smaller \( \Delta Ct \) values indicate higher expression. As shown in Figure 1A, GDF15 expression was significantly downregulated in 84.8% (56 of 66) cancerous tissues compared with normal counterparts. A paired t test was further performed, demonstrating a significant difference between NSCLC cancer tissues and normal counterparts (0.7749 ± 0.90148 versus 0.2836 ± 0.25307, \( p = 0.047 \)) (Figure 1B).

According to the median value of GDF15 expression levels, we categorized the samples into a high group (above the median, \( n = 33 \)) and a low group (below the median, \( n = 33 \)) (Figure 1C). A chi-square test was performed to evaluate clinic-pathological factors between the two groups, and the clinicopathological characteristics of the NSCLC patients are summarized in Table 1. As shown in Table 2, GDF15 levels were also correlated to age (\( p = 0.014 \)), TNM stage (\( p < 0.001 \)) and tumor size (\( p = 0.017 \)). Other clinicopathological features, such as gender and histological grade, were not statistically significant prognosis factors. Kaplan-Meier analysis and log rank test were used to evaluate the effects of GDF15 expression and the clinicopathological characteristics on overall survival (OS). Remarkably, down-expression of GDF15 was associated with a poor prognosis in patients with NSCLC (\( p < 0.001 \)) (Figure 1D). In addition, analysis of Kaplan-Meier plots of 1,926 lung cancer patients (http://www.kmplot.com) also indicated a positive relationship between GDF15 and OS (Figure 1E).

Univariate analysis identified TNM stage (I/II, III/IV) and GDF15 expression level as prognostic factors. Multivariate analysis further confirmed that a low GDF15 expression level was an independent predictor of poor survival for NSCLC (\( p = 0.036 \)) as well as TNM stage (\( p < 0.001 \)) (Table 3).

GDF15 Inhibits NSCLC Cell Proliferation and Induces Apoptosis

To evaluate the biological role of GDF15 in NSCLC, we first chose the human NSCLC cell lines SPCA1 and H1299 for further functional investigation. Then plasmid-mediated overexpression was used for exogenously manipulating the expression of GDF15 in both the
The results of the western blot showed that GDF15 expression was significantly upregulated in SPCA1 and H1299 cells transfected with pcDNA-GDF15 compared with control cells (Figure 2B). MTT assays showed that overexpression of GDF15 inhibited the proliferation of SPCA1 and H1299 cells compared with control cells (Figure 2C). Consistently, colony formation assay results revealed that clonogenic survival was inhibited after overexpression of GDF15 in SPCA1 and H1299 cells (Figure 2D). Similarly, ethynyldeoxyuridine (EdU) staining assays also indicated that overexpression of GDF15 decreased NSCLC cell proliferation (Figure 2E).

Next, flow cytometric analysis was performed to further examine whether GDF15 affected the proliferation of NSCLC cells by altering cell cycle progression. Results revealed that SPCA1 and H1299 cells transfected with pcDNA-GDF15 had increased cell cycle arrest in G0/G1 phase (Figure 3A). To determine whether NSCLC cell proliferation was influenced by cell apoptosis, we performed a flow cytometry analysis. The results showed that NSCLC cells transfected with pcDNA-GDF15 promoted apoptosis in comparison with control cells (Figure 3B). These results indicated that GDF15 could restrain NSCLC development.

**EZH2 Repressed GDF15 Expression via H3K27me3 Modification**

We explored the potential mechanism of decreased GDF15 expression in NSCLC and found that it was associated with DNA methylation. Previous studies have uncovered that histone methylation usually cooperates with DNA methylation in silencing gene activity. As an important component of methylation, histone methylation is considered an important factor in transcriptional activation and repression. Enhancer of zeste homolog 2 (EZH2) is a methyltransferase and the core catalytic subunit of polycomb repressive complex 2 (PRC2), which catalyzes the trimethylation of histone3 lysine 27 (H3K27me3) to induce chromatin compaction and transcriptional silencing of target genes that are involved in fundamental cellular processes, such as cell proliferation, cell cycle regulation, cell differentiation, and cancer. Recently accumulated evidence indicates that EZH2 is highly expressed in a wide range of cancer types, including NSCLC. In addition, several genes with a growth-inhibitory function have recently been found to be targeted by EZH2 in cancer cells. Therefore, we examined whether GDF15 could also be a key tumor suppressor gene targeted for repression by EZH2 in NSCLC.

To assess the putative role of EZH2 in GDF15 repression, we first transiently depleted the expression of EZH2 in SPCA1 and H1299 cells (Figures 4A and 4B). To avoid off-target effects, we used an interference target sequence against EZH2, as studied in a previous article. We observed that the loss of EZH2 was associated with upregulation of GDF15 at the mRNA and protein levels (Figures 4C and 4D).

To further verify the epigenetic silencing of GDF15 by EZH2, we performed chromatin immunoprecipitation (ChIP) assays to examine whether EZH2 and H3K27me3 occupy the GDF15 promoter in NSCLC cells transfected with si-EZH2 or non-specific small interfering RNA (si-NC). A nonspecific immunoglobulin G (IgG) antibody was used as a negative control. The qPCR results showed that the GDF15 promoter was enriched with endogenous EZH2 and H3K27me3, which was supported by the fact that knockdown of EZH2 expression reduced EZH2 binding and H3K27me3 modification (Figure 4E). To further validate the role of EZH2 in NSCLC, we detected the expression level of EZH2 in 30 pairs of NSCLC tissues and adjacent normal tissues. As shown in Figure 4F, EZH2 was obviously upregulated in NSCLC tissues. Finally, we verified that there

| Table 1. The Clinicopathological Factors of 66 NSCLC Patients |
|----------------|----------------|----------------|
| Clinical Factors | Number of Cases | Patients (%) |
| Sex | | |
| Male | 42 | 63.6 |
| Female | 24 | 36.4 |
| Age (Years) | | |
| ≤60 | 34 | 51.5 |
| >60 | 32 | 48.5 |
| Histological Grade | | |
| High | 7 | 10.6 |
| Middle | 23 | 34.8 |
| Middle to low | 16 | 24.2 |
| Low | 19 | 28.8 |
| Other | 1 | 1.5 |
| Histological Classification | | |
| Squamous cell carcinoma (SCC) | 40 | 60.6 |
| Adenocarcinoma (AD) | 22 | 33.3 |
| Other | 4 | 6.1 |
| Tumor Stage | | |
| I | 17 | 25.8 |
| II | 29 | 43.9 |
| III | 18 | 27.3 |
| IV | 2 | 3.0 |
| Tumor (T) | | |
| T1 | 21 | 31.8 |
| T2 | 27 | 40.9 |
| T3 | 13 | 19.7 |
| T4 | 5 | 7.6 |
| Lymph Node Metastasis (N) | | |
| N0 | 27 | 40.9 |
| N1 | 30 | 45.5 |
| N2 | 8 | 12.1 |
| N3 | 1 | 1.5 |
| History of Smoking | | |
| Ever | 39 | 59.1 |
| Never | 27 | 40.9 |
was a negative correlation between the levels of GDF15 and EZH2 expression in NSCLC tissues from The Cancer Genome Atlas (TCGA) database (Figure 4G). In addition, the EZH2 mRNA expression level was negatively correlated with GDF15 in our 30 paired NSCLC tissues (Figure 4H). These data indicated that EZH2-mediated H3K27me3 modification has a key role in the repression of GDF15 expression.

GDF15 Inhibits NSCLC Cell Tumorigenesis In Vivo
To explore whether the level of GDF15 expression could affect tumorigenesis, SPCA1 cells stably transfected with pcDNA-GDF15 or an empty vector were inoculated into male nude mice. Transplantable tumors derived from pcDNA-GDF15-transfected SPCA1 cells showed reduced tumorigenicity in athymic nude mice compared with vector-transfected SPCA1 cells. Sixteen days after the injection, the tumors formed in the pcDNA-GDF15 group were substantially smaller than those in the control group (Figures 5A and 5B). The average tumor weight in the pcDNA-GDF15 group was markedly lower than in the empty vector group (Figure 5C). In addition, qRT-PCR analysis found that the expression levels of GDF15 in tumor tissues formed from pcDNA-GDF15 cells were higher than in tumors formed in the control group (Figure 5D). Tumors formed from pcDNA-GDF15-transfected SPCA1 cells exhibited decreased positive for Ki67 and increased positive for GDF15 compared with those formed from control cells (Figure 5E). These data indicate that overexpression of GDF15 inhibits tumor growth in vivo.

DISCUSSION
NSCLC is one of the leading causes of cancer-related death worldwide. Because of late-stage diagnosis and frequency of metastasis, the 5-year survival rate for NSCLC remains poor (18.2%). In our present study, we found that expression of GDF15 in NSCLC tissues was frequently lower than in corresponding non-tumor tissues. The low expression of GDF15 in NSCLC patients was negatively correlated with advanced TNM stage and large tumor size. Importantly, decreased expression of GDF15 in NSCLC tissues was associated with a poor prognosis and could be an independent prognostic indicator. These results demonstrated that GDF15 might have an important role in NSCLC progression.

As a member of the TGF-β superfamily, GDF15 has been shown to have important roles in diverse cellular processes, such as proliferation, apoptosis, metabolism, inflammation, and immune escape. Some important clues have been obtained from studies of GDF15 gene expression and functional studies in breast cancer, glioma, prostate cancer, and intestinal adenoma. However, very little is known about the biological significance and molecular mechanisms of GDF15 in NSCLC carcinogenesis. To this end, we used gain-of-function assays to explore whether GDF15 plays a critical role in NSCLC cell proliferation. In our study, we found that overexpression of GDF15 could significantly repress NSCLC cell proliferation and induce apoptosis. These findings suggest that GDF15 functions as a tumor suppressor in NSCLC.
cell proliferation.\textsuperscript{36,37} Here we found that the mRNA levels of the epigenetic factor EZH2 were upregulated in NSCLC tissue compared with normal tissue. Knockdown of EZH2 expression significantly upregulated GDF15 expression, whereas ChIP assays showed that inhibition of EZH2 expression prevented its binding to the GDF15 promoter region and reduced H3K27me3 modification, inducing GDF15 expression. Furthermore, the EZH2 mRNA expression level was inversely correlated with GDF15 in TCGA NSCLC samples. Our previous study also found that EZH2 could epigenetically repress the expression of SPRY4 in esophageal squamous cell carcinoma.\textsuperscript{38} Overall, our data indicate that the expression of GDF15 was significantly decreased in NSCLC tissues, which was at least partially mediated by the histone methyltransferase EZH2.

In summary, this study identified that the expression of GDF15 was markedly decreased in NSCLC tissues and that its downregulation may be a negative prognostic factor for NSCLC patients for the first time. Overexpression of GDF15 repressed cell proliferation, facilitated cell apoptosis \textit{in vitro}, and inhibited tumorigenesis \textit{in vivo}. Furthermore, GDF15 undergoes transcriptional silencing in human tumorigenesis by the direct repression of an oncogenic Polycomb protein, the histone methyltransferase EZH2. EZH2-mediated inactivation of GDF15 blocks the tumor suppressor features of GDF15. Our findings elucidate a potential mechanism underlying the tumor suppressor EZH2.

### MATERIALS AND METHODS

#### Tissue Collection and Ethics Statement

A total of 66 patients analyzed in this study underwent resection of NSCLC at the First Affiliated Hospital of Nanjing Medical University. The study was approved by the Research Ethics Committee of Nanjing Medical University (Nanjing, Jiangsu, China), and written informed consent was obtained from all patients. The clinicopathological characteristics of the NSCLC patients are summarized in Table 1.

#### Cell Cultures

The NSCLC cell lines SPCA1 and NCI-H1299 were purchased from the Institute of Biochemistry and Cell Biology at the Chinese Academy of Sciences (Shanghai, China). The cells were cultured in RPMI 1640 medium or DMEM (Gibco-BRL) supplemented with 10% fetal bovine serum (FBS), 100 U/mL penicillin, and 100 mg/mL streptomycin in incubators at 37°C with 5% CO\(_2\).

#### RNA Extraction and qRT-PCR Analyses

Total RNA was extracted from tissues or cultured cells using TRIzol reagent (Invitrogen, Carlsbad, CA, USA). For qRT-PCR, RNA was reverse-transcribed to cDNA by using a reverse transcription kit (Takara, Dalian, China). Real-time PCR analyses were performed with SYBR Green (Takara, Dalian, China). Results were normalized to the expression of glyceraldehyde-3-phosphate dehydrogenase (GAPDH). The gene-specific primers were as follows: GDF15 forward, 5'-CTCCAGATTCCGAGTGTGC-3' and reverse, 5'-TGCACATCCTGACTTCTGTG-3'; GAPDH forward, 5'-AGGCCCAT CGCTCGACAC-3' and reverse, 5'-GCCAATAGGCGCAAAAT CC-3'; EZH2 forward, 5'-TGCAATCCTGTACTTCTGTG-3' and reverse, 5'-AAGGCGATTCCACAACTC-3'. qRT-PCR and data collection were carried out on an ABI 7500 real-time PCR system (Applied Biosystems, Foster City, CA, USA). The relative expression of GDF15 was calculated and normalized using the 2\(^{-}\Delta\Delta C_{T}\) method relative to GAPDH.

#### Transfection of Cell Lines

The GDF15 sequence was synthesized according to the full-length GDF15 sequence and then subcloned into a pcDNA3.1 vector (Invitrogen, China). The empty pcDNA3.1 vector was used as the control. The plasmid was transfected by X-treme GENE HP DNA transfection reagent (Roche, Basel, Switzerland) according to the manufacturer's instructions. The nucleotide sequences of small interfering RNAs (siRNAs) for EZH2 were as follows: sense, 5'-GAGGGUUCAGAC GAGCUCAUUU-3'; antisense 5'-AAAAUCACUGUCUGAC CUC-3'. si-NC was purchased from Invitrogen. Typically, cells were seeded in six-well plates and then transfected the next day.
with specific siRNA (100 nM) and control siRNA (100 nM) using Lipofectamine RNAi MAX according to the manufacturer’s protocol (Invitrogen). 48 hr post-transfection, cells were harvested and processed for the following experiments.

**Flow Cytometric Analysis**

Cells were harvested after transfection by trypsinization. For cell cycle analysis, cells were stained with propidium oxide using the Cycle Test Plus DNA Reagent Kit (BD Biosciences) following the manufacturer’s protocol and then analyzed by flow cytometry (FACScan, BD Biosciences). The percentage of cells in G0/G1, S, and G2/M phase were counted and compared. Double staining with fluorescein isothiocyanate (FITC)-Annexin V and propidium iodide was done using the FITC Annexin V Apoptosis Detection Kit (BD Biosciences) according to the manufacturer’s recommendations. The cells were analyzed with a flow cytometer (FACScan, BD Biosciences) equipped with Cell

---

**Figure 2. Effects of GDF15 on NSCLC Cell Proliferation In Vitro**

(A and B) qRT-PCR and western blot analysis of the GDF15 expression level in SPCA1 (A) and H1299 (B) cells transfected with the pcDNA-GDF15 vector. GAPDH protein expression was used as an internal control. (C) MTT assays were used to determine the viability of pcDNA-GDF15-transfected SPCA1 and H1299 cells. (D) Colony formation assays were performed to determine the proliferation of pcDNA-GDF15-transfected SPCA1 and H1299 cells. Colonies were counted and captured. (E) EdU (red) or DAPI (blue) assays were conducted 24 hr after transfection to determine the viability of the transfected SPCA1 and H1299 cells. The data represent the mean ± SD from three independent experiments. *p < 0.05 and **p < 0.01.
Quest software (BD Biosciences). Cells were discriminated into viable cells, dead cells, early apoptotic cells, and apoptotic cells, and then the relative ratio of early apoptotic cells was compared with control transfection from each experiment. All of the samples were assayed in triplicate.

**EdU Analysis**

An EdU labeling or detection kit (Ribobio, Guangzhou, China) was used to assess cell proliferation. The cells were cultured in 96-well plates at $5 \times 10^3$ cells/well. Forty-eight hours after transfection, 50 μM EdU labeling medium was added to the 96-well plates, and they were incubated for 2 hr at 37°C under 5% CO₂.

After treatment with 4% paraformaldehyde and 0.5% Triton X-100, the cells were stained with anti-EdU working solution. DAPI was used to label the cell nuclei. The percentage of EdU-positive cells was calculated after fluorescence microscopy analysis. Five fields of view were randomly assessed for each treatment group.

**ChIP Assays**

ChIP assays were performed using EZ-CHIPKIT according to the manufacturer’s instructions (Millipore, USA). The EZH2 antibody was obtained from Millipore. H3 trimethyl Lys 27 antibody was purchased from Abcam. Quantification of
immunoprecipitated DNA was performed using qPCR with SYBR Green Mix (Takara). The ChIP primer sequences (forward 5'-GTATTCTCATGCAGATTCCGTT-3' and reverse 5'-CCACTTCTTGTGACCGCA-3') were used to amplify the promoter region of GDF15. ChIP data were calculated as a percentage relative to the input DNA by the following equation: 2^{\Delta\Delta Ct} = 2^{\text{Input Ct} - \text{Target Ct}} / 2^{\text{Ct}0} \times 100.

**Tumor Formation Assay in a Nude Mouse Model**

Five-week-old male athymic BALB/c mice were maintained under specific pathogen-free conditions and manipulated according to protocols approved by the Shanghai Medical Experimental Animal Care Commission. SPCA1 cells transfected with the pcDNA3.1 vector or pcDNA-GDF15 were harvested at a concentration of 2 × 10^7 cells/mL. Of the suspended cells, 0.1 mL was subcutaneously injected into either side of the posterior flanks of the nude mouse. Tumor volumes and weights were examined every 2 days in mice from the control (seven mice) or pcDNA-GDF15 (seven mice) group; tumor volumes were measured (length × width^2 × 0.5). Sixteen days after injection, the mice were killed, and tumor weights were measured and used for further analysis. The primary tumors were excised, and tumor tissues were used to perform qRT-PCR analysis of GDF15 levels and immunostaining analysis of Ki-67 and GDF15 protein expression.

**Statistical Analysis**

Statistical analysis was performed using SPSS version 22 software (Chicago, IL). Chi-square and t tests were performed to explore the associations between the GDF15 expression level and the clinical characteristics. The survival curves were estimated using the Kaplan-Meier method. A log rank test was used to estimate the significance of the differences between the survival curves. A Cox proportional hazards analysis was performed to calculate the hazard ratio (HR) and the 95% confidence interval (CI) to evaluate the association between GDF15 expression and OS. A multivariate Cox regression was performed to adjust for other
covariates. p values less than 0.05 were considered to be statistically significant.

AUTHOR CONTRIBUTIONS
X. Lu, X.H., J.S., and J.W. contributed to designing and organizing the experiments, carrying out data analysis, and writing the manuscript. X. Liu, K.X., and W.D. contributed to laboratory measurements and data analysis. Y.E.S., R.G., and E.Z. contributed to conceiving the ideas, supervising the study, and writing the manuscript. All authors read and approved the final manuscript.

CONFLICTS OF INTEREST
The authors declare that they have no competing interests.

ACKNOWLEDGMENTS
This work was supported by grants from the National Natural Science Foundation of China (81702266, 81230054, 91029739, and 81172217), the National Key Technology R&D Program for the 12th Five-Year Plan of China (2013BAI01B06), the State Key Laboratory of Reproductive Medicine, Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD), the Natural Science Foundation of Jiangsu Province (BK20161593), the Medical Important Talent Foundation of Jiangsu Province (RC201157), and the Wu Jie-ping Foundation (320.6799.15032). This work was also supported by the China Postdoctoral Science Foundation (2017M610339), Jiangsu Planned Projects for Postdoctoral Research Funds (1701041A), and the Scientific Foundation of Wuxi City of Jiangsu (Q201728).

REFERENCES
1. Siegel, R., Naishadham, D., and Jemal, A. (2013). Cancer statistics, 2013. CA Cancer J. Clin. 63, 11–30.
2. Jemal, A., Bray, F., Center, M.M., Ferlay, J., Ward, E., and Forman, D. (2011). Global cancer statistics. CA Cancer J. Clin. 61, 69–90.
3. Baek, S.J., Kim, K.S., Nixon, J.B., Wilson, L.C., and Eling, T.E. (2001). Cyclooxygenase inhibitors regulate the expression of a TGF-beta superfamily member that has proapoptotic and antitumorigenic activities. Mol. Pharmacol. 59, 901–908.
4. Yokoyama-Kobayashi, M., Saeki, M., Sekine, S., and Kato, S. (1997). Human cDNA encoding a novel TGF-beta superfamily protein highly expressed in placenta. J. Biochem. 122, 622–626.
5. Böttner, M., Suter-Crazzolara, C., Schober, A., and Unsicker, K. (1999). Expression of a novel member of the TGF-beta superfamily, growth/differentiation factor-15/macrophage inhibiting cytokine-1 (GDF-15/MIC-1) in adult rat tissues. Cell Tissue Res. 297, 103–110.
6. Strelau, J., Böttner, M., Lingor, P., Suter-Crazzolara, C., Galter, D., Jaszai, J., Sullivan, A., Schober, A., Kriegstein, K., and Unsicker, K. (2000). GDF-15/MIC-1 a novel member of the TGF-beta superfamily. J. Neural Transm. Suppl. 60, 273–276.
7. Paralkar, V.M., Vail, A.L., Grassner, W.A., Brown, T.A., Xu, H., Vukicsevic, S., Ke, H.Z., Qi, H., Owen, T.A., and Thompson, D.D. (1998). Cloning and characterization of a novel member of the transforming growth factor-beta/bone morphogenetic protein family. J. Biol. Chem. 273, 13760–13767.
8. Kim, K.S., Baek, S.J., Flake, G.P., Loftin, C.D., Calvo, B.F., and Eling, T.E. (2002). Expression and regulation of nonsteroidal anti-inflammatory drug-activated gene (NAG-I) in human and mouse tissue. Gastroenterology 122, 1388–1398.
9. Baek, S.I., Okazaki, R., Lee, S.H., Martinez, J., Kim, J.S., Yamaguchi, K., Mishina, Y., Martin, D.W., Shoieb, A., McIntee, M.F., and Eling, T.E. (2006). Nonsteroidal anti-inflammatory drug-activated gene-1 over expression in transgenic mice suppresses intestinal neoplasia. Gastroenterology 131, 1553–1560.
10. Baek, S.I., Kim, J.S., Moore, S.M., Lee, S.H., Martinez, J., and Eling, T.E. (2005). Cyclooxygenase inhibitors induce the expression of the tumor suppressor gene

Figure 5. GDF15 Inhibits the Tumorigenesis of NSCLC Cells In Vivo
(A) Empty vector or pcDNA-GDF15 was transfected into SPCA1 cells, which were then injected individually into nude mice (n = 5). (B) The tumor volumes were calculated every 2 days after injection. The mean tumor volumes are indicated by points, and the bars indicate SD (n = 5). (C) The tumor weights are represented as the mean tumor weights ± SD (n = 5). (E) The tumor sections were examined using H&E staining and IHC staining with antibodies against Ki-67 and GDF15. Left: representative images. Right: statistical analysis. The error bars indicate the mean ± standard error. *p < 0.05 and **p < 0.01.
Molecular Therapy: Nucleic Acids  Vol. 12  September 2018

EGR-1, which results in the up-regulation of NAG-1, an antitumorigenic protein. Mol. Pharmacol. 67, 356–364.

Baek, S.I., Wilson, L.C., Lee, C.H., and Eling, T.E. (2002). Dual function of nonsteroidal anti-inflammatory drugs (NSAIDs): inhibition of cyclooxygenase and induction of NSAID-activated gene. J. Pharmacol. Exp. Ther. 301, 1126–1131.

Liu, T., Bauskin, A.R., Zaunders, J., Brown, D.A., Pankhurst, S., Russell, P.J., and Breit, S.N. (2003). Macrophage inhibitory cytokine 1 reduces cell adhesion and induces apoptosis in prostate cancer cells. Cancer Res. 63, 5034–5040.

Roth, P., Junker, M., Triticshler, I., Mittelbron, M., Dombrowski, Y., Breit, S.N., Tabatabai, G., Wick, W., Weller, M., and Wischhusen, J. (2010). GDF-15 contributes to proliferation and immune escape of malignant gliomas. Clin. Cancer Res. 16, 3851–3859.

Ratnam, N.M., Peterson, J.M., Talbert, E.E., Ladner, K.J., Rajasekera, P.V., Schmidt, C.R., Dillhoff, M.E., Swanson, B.J., Haverick, E., Kladny, R.D., et al. (2017). NF-kB regulates GDF-15 to suppress macrophage surveillance during early tumor development. J. Clin. Invest. 127, 3796–3809.

Monteiro-Reis, S., Leça, L., Almeida, M., Antunes, L., Monteiro, P., Dias, P.C., Morais, A., Oliveira, J., Henrique, R., and Jerónimo, C. (2014). Accurate detection of upper tract urothelial carcinoma in tissue and urine by means of quantitative GDF15, TMEFF2 and VIM promoter methylation. Eur. J. Cancer 50, 226–233.

Viré, E., Brenner, C., Deplus, R., Blanchon, L., Fraga, M., Didot, C., Morey, L., Van Eynde, A., Bernard, D., Vanderwinden, J.M., et al. (2006). The Polycomb group protein EZH2 directly controls DNA methylation. Nature 439, 871–874.

Fahrner, I.A., Eguchi, S., Herman, J.G., and Baylin, S.B. (2002). Dependence of histone modifications and gene expression on DNA hypermethylation in cancer. Cancer Res. 62, 7213–7218.

McGrath, J., and Trojer, P. (2015). Targeting histone lysine methylation in cancer. Pharmacol. Ther. 150, 1–22.

Kim, K.H., and Roberts, C.W. (2016). Targeting EZH2 in cancer. Nat. Med. 22, 128–134.

Di Croce, L., and Helin, K. (2013). Transcriptional regulation by Polycomb group proteins. Nat. Struct. Mol. Biol. 20, 1147–1155.

Margueron, R., and Reinberg, D. (2011). The Polycomb complex PRC2 and its mark in life. Nature 469, 343–349.

Behrens, C., Solis, L.M., Lin, H., Yuan, P., Tang, X., Kadara, H., Riquelme, E., Galindo, H., Moran, C.A., Kalhorn, N., et al. (2013). EZH2 protein expression associates with the early pathogenesis, tumor progression, and prognosis of non-small cell lung carcinoma. Clin. Cancer Res. 19, 6556–6565.

Kleer, C.G., Cao, Q., Varambally, S., Shen, R., Ota, I., Tomlins, S.A., Ghosh, D., Sewalt, R.G., Otte, A.P., Hayes, D.F., et al. (2003). EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc. Natl. Acad. Sci. USA 100, 11606–11611.

Matsukawa, Y., Semb, S., Kato, H., Ito, A., Yanagihara, K., and Yokozaki, H. (2006). Expression of the enhancer of zeste homolog 2 is correlated with poor prognosis in human gastric cancer. Cancer Sci. 97, 484–491.

25. Lu, C., Han, H.D., Mangala, I.S., Ali-Fehmi, R., Newton, C.S., Ozburn, L., Armaiz-Pena, G.N., Hu, W., Stone, R.L., Munkarah, A., et al. (2010). Regulation of tumor angiogenesis by EZH2. Cancer Cell 18, 185–197.

26. Beke, L., Nuytten, M., Van Eynde, A., Beudelns, M., and Bollen, M. (2007). The gene encoding the prototypical tumor suppressor P53 is a target for repression by the Polycomb group protein EZH2. Oncogene 26, 4590–4595.

27. Yu, J., Cao, Q., Mehra, R., Laxman, B., Yu, J., Tomlins, S.A., Creighton, C.J., Dhanasekaran, S.M., Shen, R., Chen, G., et al. (2007). Integrative genomics analysis reveals silencing of beta-adrenergic signaling by polycomb in prostate cancer. Cancer Cell 12, 419–431.

28. Taniguchi, H., Jacinto, F.V., Villanueva, A., Fernandez, A.F., Yamamoto, H., Carmona, F.J., Puertas, S., Marquez, V.E., Shimomura, Y., Imai, K., and Esteller, M. (2012). Silencing of Kruppel-like factor 2 by the histone methyltransferase EZH2 in human cancer. Oncogene 31, 1988–1994.

29. Prensner, J.R., Iyer, M.K., Balbin, O.A., Dhanasekaran, S.M., Cao, Q., Brenner, J.C., Laxman, B., Asangani, I.A., Grasso, C.S., Kominsky, H.D., et al. (2011). Transcriptome sequencing across a prostate cancer cohort identifies PCAT-1, an unannotated lincRNA implicated in disease progression. Nat. Biotechnol. 29, 742–749.

30. DeSantis, C.E., Lin, C.C., Mariotto, A.B., Siegel, R.L., Stein, K.D., Kramer, J.L., Alteri, R., Robbins, A.S., and Jemal, A. (2014). Cancer treatment and survivorship statistics, 2014. CA Cancer J. Clin. 64, 252–271.

31. Lee, S.E., Kang, S.G., Choi, M.J., Jung, S.B., Ryu, M.J., Chung, H.K., Chang, J.Y., Kim, Y.K., Lee, J.H., Kim, K.S., et al. (2017). Growth Differentiation Factor 15 Mediates Systemic Glucose Regulatory Action of T-Helper Type 2 Cytokines. Diabetes 66, 2774–2788.

32. Li, P.X., Wong, J., Ayed, A., Ngo, D., Brade, A.M., Arrowsmith, C., Austin, R.C., and Eling, T.E. (2012). DNA methylation-mediated silencing of nonsteroidal anti-inflammatory drug-activated gene (NAG-1/GDF15) in glioma cell lines. Int. J. Cancer 130, 267–277.

33. Kadowaki, M., Yoshioka, H., Kamitani, H., Watanabe, T., Wade, P.A., and Eling, T.E. (2012). DNA methylation-mediated silencing of nonsteroidal anti-inflammatory drug-activated gene (NAG-1/GDF15) in glioma cell lines. Int. J. Cancer 130, 267–277.

34. Kadowaki, M., Yoshioka, H., Kamitani, H., Watanabe, T., Wade, P.A., and Eling, T.E. (2012). DNA methylation-mediated silencing of nonsteroidal anti-inflammatory drug-activated gene (NAG-1/GDF15) in glioma cell lines. Int. J. Cancer 130, 267–277.

35. Cao, R., Wang, L., Wang, H., Xia, L., Erdjument-Bromage, H., Tempst, P., Jones, R.S., and Zhang, Y. (2002). Role of histone H3 lysine 27 methylation in Polycomb-group silencing. Science 298, 1039–1043.

36. Chang, C.J., and Hung, M.C. (2012). The role of EZH2 in tumour progression. Br. J. Cancer 106, 243–247.

37. Chae, A., and Gross, N.C. (2011). Aberrations of EZH2 in cancer. Clin. Cancer Res. 17, 2613–2618.

38. Zhang, E., Han, L., Yin, D., He, X., Hong, L., Si, X., Qiu, M., Xu, T., De, W., Xu, L., et al. (2017). H3K27 acetylation activated-long non-coding RNA CCAT1 affects cell proliferation and migration by regulating SPRY4 and HOXB13 expression in esophageal squamous cell carcinoma. Nucleic Acids Res. 45, 3086–3101.